Clinical trial
A Phase 1/2, Baseline-controlled, Non-randomized, Open-label, Single-ascending Dose Study of a Novel Adeno-associated Viral Vector (FLT190) in Patients With Fabry Disease
NCT04040049 is registered in ClinicalTrials.gov with Spur Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, Baseline-controlled, Non-randomized, Open-label, Single-ascending Dose Study of a Novel Adeno-associated Viral Vector (FLT190) in Patients With Fabry Disease
- Lead sponsor
- Spur Therapeutics
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- July 8, 2019
- Completion date
- May 2, 2023
- Enrollment
- 3 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.